<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Background: Associations between elevated C-reactive protein (CRP) and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk have been reported for many years, but the results from prospective cohort studies remains controversial </plain></SENT>
<SENT sid="1" pm="."><plain>A meta-analysis of prospective cohort studies was therefore conducted to address this issue </plain></SENT>
<SENT sid="2" pm="."><plain>Methods: Eligible studies were identified by searching the PubMed and EMBASE up to October 2012 </plain></SENT>
<SENT sid="3" pm="."><plain>Pooled hazard ratios (HR) was calculated by using random effects model </plain></SENT>
<SENT sid="4" pm="."><plain>Results: Eleven prospective cohort studies involving a total of 194,796 participants and 11,459 cancer cases were included in this meta-analysis </plain></SENT>
<SENT sid="5" pm="."><plain>The pooled HR per natural log unit change in CRP was 1.105 (95% confidence interval (CI): 1.033-1.178) for <z:hpo ids='HP_0000001'>all</z:hpo>-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, 1.308 (95% CI: 1.097-1.519) for <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e>, 1.040 (95% CI: 0.910-1.170) for <z:hpo ids='HP_0003002'>breast cancer</z:hpo>, 1.063 (95% CI: 0.965-1.161) for <z:hpo ids='HP_0012125'>prostate cancer</z:hpo>, and 1.055 (95% CI: 0.925-1.184) for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Dose-response analysis showed that the exponentiated linear trend for a change of one natural log unit in CRP was 1.012 (95% CI: 1.006-1.018) for <z:hpo ids='HP_0000001'>all</z:hpo>-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>No evidence of publication bias was observed </plain></SENT>
<SENT sid="8" pm="."><plain>Conclusions: The results of this meta-analysis showed that the elevated levels of CRP are associated with an increased risk of <z:hpo ids='HP_0000001'>all</z:hpo>-<z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">cancer, lung</z:e> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, and possibly breast, prostate and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>The result supports a role of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mp ids='MP_0001845'>inflammation</z:mp> in <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Further research effort should be performed to identify whether CRP, as a marker of <z:mp ids='MP_0001845'>inflammation</z:mp>, has a direct role in <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
</text></document>